Hypophosphatasia, a rare inherited disorder characterized by defective bone mineralization, is highly variable in its clinical expression. The disease is due to various mutations in the tissue-non-specific alkaline phosphatase (TNSALP) gene. We report here the use of clinical data, site-directed mutagenesis and computer-assisted modelling to propose a classification of 32 TNSALP gene mutations found in 23 European patients, 17 affected with lethal hypophosphatasia and six with non-lethal hypophosphatasia. Transfection studies of the missense mutations found in non-lethal hypophosphatasia showed that six of them allowed significant residual in vitro enzymatic activity, suggesting that these mutations corresponded to moderate alleles. Each of the six patients with non-lethal hypophosphatasia carried at least one of these alleles. The three-dimensional model study showed that moderate mutations were not found in the active site, and that most of the severe missense mutations were localized in crucial domains such as the active site, the vicinity of the active site and homodimer interface. Some mutations appeared to be organized in clusters on the surface of the molecule that may represent possible candidates for regions interacting with the C-terminal end involved in glycosylphosphatidylinositol (GPI) attachment or with other dimers to form tetramers. Finally, our results show a good correlation between clinical forms of the disease, mutagenesis experiments and the three-dimensional structure study, and allowed us to clearly distinguish moderate alleles from severe alleles. They also confirm that the extremely high phenotypic heterogeneity observed in patients with hypophosphatasia was due mainly to variable residual enzymatic activities allowed by missense mutations found in the human TNSALP gene.
INTRODUCTION
Hypophosphatasia is an inherited disorder characterized by defective bone mineralization and deficiency of serum and liver/bone/kidney alkaline phosphatase (L/B/K ALP) activity. The disease is highly variable in its clinical expression, which ranges from stillbirth without mineralized bone to pathological fractures developing only late in adulthood (1) . Depending on the age at diagnosis, five clinical forms currently are recognized: perinatal, infantile, childhood, adult and ondotohypophosphatasia. Severe forms of the disease (perinatal and infantile) are transmitted as an autosomal recessive trait, while the mode of inheritance of clinically more mild childhood hypophosphatasia or adult hypophosphatasia remains uncertain, and both autosomal recessive and autosomal dominant transmission have been suggested (2, 3) . Heterozygous carriers of the severe forms are usually clinically normal but often show modestly reduced serum ALP activity and increased urinary phosphoethanolamine. The tissue-non-specific alkaline phosphatase (TNSALP) is a phosphomonoesterase anchored at its C-terminus to the plasma membrane by a phosphatidylinositol-glycan moiety (4) . Its presumed cell surface tetrameric structure is orientated so that the active sites face the extracellular environment. The markedly variable clinical expressivity of hypophosphatasia has been studied previously by measuring serum ALP, plasma levels of pyridoxal 5'-phosphate or urinary phosphoethanolamine, or by examining biochemical properties of ALPs in cultured fibroblasts of patients (5) , and the biochemical parameters accounting for clinical severity are now clearly determined. However, to date, little is known about the relationships between phenotypic variability and mutations of the gene responsible for the disease.
The TNSALP gene is localized on chromosome 1p36.1-34 (6) and consists of 12 exons distributed over 50 kb (7) . More than 54 distinct mutations have been described in the TNSALP gene in a relatively small number of North American, Japanese and European patients (8) (9) (10) (11) (12) (13) (14) (15) (16) , indicating a very strong allelic heterogeneity in the disease. Most of them (85%) were missense mutations. This variety of mutations probably results in variable clinical expressivity among even the severe types, with the direct consequence that correlations between genotype and phenotype are difficult to establish because most of the patients are compound heterozygotes, making it difficult to determine the respective roles of missense mutations. Site-directed mutagenesis and transfection analysis of TNSALP cDNA may help to solve this problem by determining the relationship between the individual tested mutation and the phenotype through ALP activity (15, 17, 18) . Computer-assisted modelling of proteins may also help us to understand a mutation effect, through localization of the residues within the protein, according to the nature of their relationships with nearby residues and critical domains such as the active site, ligand-binding site and homodimer interface. By means of clinical data, site-directed mutagenesis and computerassisted modelling, we propose a classification of TNSALP mutations found in European patients with severe or non-lethal hypophosphatasia.
RESULTS

Clinical data
According to available information concerning age at diagnosis and survival age, the 23 hypophosphatasia cases studied in our laboratory were separated into two distinct phenotypes (Table 1) : lethal (including perinatal and infantile forms lethal in the first year of life) and non-lethal (including other infantile and childhood forms). Information concerning serum ALP and TNSALP substrate levels was too incomplete to be used for correlations. Seventeen patients were affected with lethal hypophosphatasia and six with the non-lethal form of the disease. Among the 32 distinct mutations found, 25 were missense mutations and the other seven were nonsense or frameshift mutations or mutations affecting splicing (14, 16) . Except for mutation 1172delC, all the nonsense and frameshift mutations as well as the mutations affecting splicing were found in patients with severe hypophosphatasia. As observed previously (1, 5) , there is a continuity in the severity of the disease so that unambiguous distinction of close clinical forms remains uncertain. In the case of recessively transmitted hypophosphatasia, the phenotype of a patient was expected to be the result of the less severe allele carried by this patient. Thus, patients with lethal hypophosphatasia were expected to carry two severe alleles while patients with non-lethal hypophosphatasia were expected to carry two moderate alleles or only one moderate allele associated with a severe allele.
Transfection studies
Site-directed mutagenesis of wild-type cDNAs with missense mutations found in patients with non-lethal hypophosphatasia was performed to identify the moderate alleles. Four mutations found in patients with lethal hypophosphatasia (W253X, A23V, R433C and S428P) were also analysed: W253X, because no ALP activity was expected from cDNA mutagenized with this mutation which consequently was used as negative control; R433C, because this mutation was found to be homozygous in two unrelated patients with severe but obviously different clinical forms (Table 1) ; and A23V and S428P, because no strong evidence of the disease-causing role of these mutations was obtained previously. The results are shown in Table 2 . In the experimental conditions used in this study (see Materials and Methods), mean TNSALP production by the wild-type cDNA was 22.5 U/l (22.2-22.9), a value 45-fold higher than the mean value found in untransfected cells. In order to compare the mutation effects, each ALP value was weighted with the β-galactosidase activity of co-transfected plasmids and expressed as a percentage of the wild-type activity (%WT). The plasmid with W253X showed a mean value of 1.2%WT (0.5-1.8) corresponding to the background of the experiments. As shown by the standard deviation, duplicate and/or triplicate assays of the same mutation showed low variations of ALP activity, indicating that the observed variations between distinct mutations were not due to experimental artefacts but correspond to the expression of TNSALP by the mutagenized cDNA. ALP values were highly variable, ranging from 1.3 to 88%WT, a result that would require correlation with the extremely high variability of phenotypes previously observed with clinical data. The mutations were sorted into two distinct groups, those with no or very low ALP activity (A23V, G58S, G145V, H154Y, S428P and R433C) that should therefore correspond to severe alleles, and those with significantly higher ALP values (S-1F, M45L, R119H, E174K, E274K and R374K) that could correspond to moderate alleles. With a value of 4.0%WT, the R433C mutation appears to represent the limit between severe and moderate alleles. This is supported by the fact that this mutation was found in two distinct homozygous patients with lethal hypophosphatasia, one of whom exhibited the infantile form of the disease (Table 1) . Interestingly, each patient with non-lethal hypophosphatasia was found to carry at least one of these six moderate alleles, associated or not with a severe allele ( Table 1) . This indicates that infantile and childhood hypophosphatasias may be due to compound heterozygosity of severe and moderate alleles.
The polymorphism Y246H was described previously in the North American population with a frequency of 33% (9) . Analysis of 52 unrelated normal individuals from the French population and 40 unrelated parents of patients showed that H246 allele frequency was 8 and 10%, respectively. In three patients, we found Y246H associated on the same chromosome with mutations G145V, H154Y or 1171delC. To investigate the possible role of H246 in ALP function, we mutagenized TNSALP cDNA with this polymorphism associated or not with mutation G145V. The results clearly showed that H246 had no effect on the production of active ALP and may be considered as a normal allele (Table 2) .
Computer-assisted modelling
On the basis of clinical data and transfection studies, 26 of the 32 mutations found in our patients corresponded to severe alleles and six to moderate ones (Tables 1 and 2 ). As expected, severe mutations comprised nonsense and frameshift mutations, but also the three mutations affecting splicing and 16 missense mutations. These missense mutations as well as the six moderate mutations subsequently were classified according to their position in the TNSALP molecule. Alignment of Escherichia coli and human genes, and the three-dimensional model in the PDB file, are available on the Internet site ftp://proline.jouy.inra.fr/pub/TNSALP/ . The alignment mostly agrees with a previously reported alignment (7), except in two regions including the first 33 residues of the molecule and residues 436-450. A loop of 27 residues, from V407 to R433, was too large to be modelled correctly by the program, and the three-dimensional structure in this region remains tentative.The 15 residues forming the active site of the human TNSALP (D43, D92, S93, A94, H154, T156, R167, Y170, E315, D320, H324, D361, H362, H364 and H437) were defined according to the active site region of E.coli ALP defined previously (19) .
The missense mutations were sorted into six groups according to their location in the three-dimensional model (Table 3 ; Fig. 1a ).
(i) Missense mutations directly affecting the active site. Three severe mutations affected the active site, A94T, H154Y and R167W. Ala94 is involved in the hydrogen bond network of the active site through an interaction with Asp92. Its replacement would presumably disturb the hydrogen bond network in this critical area. H154 is the only residue of the active site that is not conserved. In the alignment, H154 corresponds to D153 of the E.coli ALP sequence. According to Kim and Wyckoff (20) , D153 is not a direct ligand but forms hydrogen bonds with two water molecules that are co-ordinating Mg 2+ . A similar role as a bidentate ligand can be played by H154 in hTNS-ALP, except that instead of having two acceptors (the two oxygens of the carbonyl group) it has one acceptor (the imidazole nitrogen) and one donor (the hydrogen of the amide group). It has been suggested (21) that the 20-to 30-fold increase in activity of mammalian ALPs compared with the corresponding bacterial enzymes could be explained by the substitution of D153 and K328 by two histidines (H154 and H321 in our model). Replacing His154 by a tyrosine, which has only one site for a hydrogen bond, might result in destabilization of the Mg 2+ co-ordination and, thus, perturbation of the active site. This is corroborated by our transfection study showing that Y154 mutant cells expressed almost no residual enzymatic activity (2.1%WT). According to the three-dimensional model of human TNSALP, Arg167 is directly involved in the fixation of the phosphate ligand, tightly holding two of the four oxygens of the phosphate with the two amino functions of its guanidium group, the other two oxygens atoms of the phosphate being co-ordinated to the Zn atoms of the active site. A tryptophan molecule at this position would presumably prevent co-ordination of the phosphate ion since this amino acid does not carry the required amino functions.
(ii) Missense mutations affecting amino acids close to the active site. Severe mutations G103R, N153D and G317D and the moderate mutation M45L were found at distances from residues of the active site ranging from 3.6 (for G317D) to 13 Å (for G103R). The G103 residue constitutes a turn at the junction of an α-helix including residues from the active site, and its replacement by arginine may modify the orientation of this α-helix. N153D was found in the homozygous state in a patient affected by lethal neonatal hypophosphatasia. This residue is located in a loop, close to the active site positions H154 and T156. This position is occupied by a glutamine in the E.coli ALP sequence, suggesting that an amide group might be necessary at this position for correct enzymatic activity. Mutation G317D was found to be homozygous in a patient with perinatal lethal hypophosphatasia. This mutation was also found in other populations in patients also affected with lethal hypophosphatasia (10) . G317 is located between a helix and a strand, and it establishes hydrogen bonds with residues E315 and D320, two residues belonging to the active site. E315 is involved in Mg 2+ co-ordination, and D320 in Zn 2+ coordination (20) . As it has no side chain, glycine is a special residue and its replacement by an aspartate is likely to disturb the structure locally. Transfections of COS cells showed that G317D completely abolishes enzymatic activity and that the mutant failed to reach the cell surface and was rapidly degraded (17) . These results as well as our own clearly demonstrate that G317D is a severe hypophosphatasia allele. Mutation M45L, which is also found in the vicinity of the active site, is a rather conservative mutation in terms of physico-chemical properties of the side chains. The mutation does not seem to generate important changes in bulk, polarity or secondary structure. This may explain why this substitution allows residual enzymatic activity in transfection studies.
(iii) Missense mutations possibly affecting the homodimer interface. The distances between residues A23, G58 and R374C and residues from the other monomer were~8 Å. Although these distances are not short enough to involve these residues directly in homodimer interactions, they may play a role in maintaining the correct structure allowing these interactions (Fig. 1b) . Mutations A23V and G58S correspond to severe alleles and R374C to a moderate one. The absence of active ALP production may be explained by the absence of a stable homodimer, while residual ALP activity may result from a deficit of functional homodimers.
(iv) Two clusters on the surface of the molecule. Mutations G112R, R119H, E174K and C184Y appear to be organized into a cluster on the surface of the molecule, on the side of the active site. G112R and C184Y correspond to severe alleles, R119H and E174K to moderate ones. A second cluster is localized on the face opposite the dimer interface. It comprises residues R206W, G232V and D289V. Mutations of these three residues are responsible for severe alleles. Mutation D289V is unusual, as a valine is precisely the residue that occurs in the E.coli sequence. The region encompassing residues 240-290 of human TNSALP is not particularly well conserved between the E.coli and human sequences, and local misalignment in this region cannot be excluded here.
Because residues on the surface of the protein are not supposed to play an important structural role, one expects less stringent conditions to prevail for replacing residues. In the present case, this appears to be corroborated by the fact that five out of the seven residues involved in these clusters are not conserved between the E.coli sequence and the human TNS-ALP sequence ( Table 3 ), and that two of them correspond to moderate alleles. One explanation for the resulting severity of some of the mutations found in these two surface clusters would be that they belong to an area of the molecule that needs to interact with other actors of the biological system, such as the C-terminal end of the protein involved in glycosylphosphatidylinositol (GPI) attachment (7, 22) or with another dimer to form a tetramer (5).
(v) Other alleles. Mutations G145V and E274K do not belong to the previous categories. Gly145, which is buried in the three-dimensional structure, might thus be a structurally important residue. This is supported by the fact that glycine is conserved in the E.coli sequence and may explain why G145V was found as a severe allele. In contrast, residue E274 was found to be conserved in ALP and TNSALP from various species (14) but not in E.coli ALP. Moreover, this residue was found on the outside of the molecule, in a non-crucial area, and there is a lysine residue at this position in E.coli. This may explain why mutation E274K allowed residual in vitro ALP activity.
Mutations S428P, R433C, G456S, E459K and G474R were not included in the three-dimensional model. The first two are part of a long insertion loop that cannot be modelled reliably by the program. The last three belong to the C-terminal part that has no equivalent in the E.coli structure. It has been suggested that the C-terminus of the human protein may serve as anchor membrane domains (7) or allow covalent attachment to the GPI moiety of membranes (22) . Mutations in this part of the molecule may therefore result in normal production of active enzyme which may not be bound correctly to the membrane.
Because it does not belong to the mature active protein, the signal peptide was not included in the E.coli and human three- dimensional models. Mutation S-1F was therefore not analysed. According to mutagenesis experiments and clinical data, this mutation seems to have a moderate effect on the protein function. However, the mutation results in decreased enzymatic activity and probably affects final processing of the protein, perhaps by preventing its migration to the cell membrane. It is therefore possible that S-1F partially allows correct processing or that unprocessed protein succeeds in binding the membrane but is incompletely active.
DISCUSSION
In this study, we tried to correlate the nature of the TNSALP mutation and the phenotype of hypophosphatasia, by using clinical data, site-directed mutagenesis and computer-assisted modelling. These complementary approaches allowed us to identify the phenotype-causing nature of some mutations. An example may be illustrated by the patient Re1, affected by childhood hypophosphatasia and who carries the mutations R119H and G145V. Site-directed mutagenesis showed that R119H expressed residual activity (33.4%WT), suggesting that this mutation could be less severe than G145V (1.3%WT). According to our previous classification, R119H may therefore be a moderate allele and G145V a severe one. Threedimensional modelling may complete our understanding of this mutation by identifying the nature of the domain (active site, homodimer interface, GPI attachment) in which the mutated residue is involved and its possible interactions with other residues. In this example, Gly145 was found buried in the molecule and may therefore have a structural function, while Arg119 was localized on the surface of the protein in a region where it is unlikely that residues play a structural role. A second example is the case of the substitution A23V. The absence of significant activity produced by cells transfected with the A23V mutation strongly suggests that this amino acid is crucial for correct enzymatic activity and confirms the disease-causing role of this mutation. The three-dimensional model showed that residue A23 was localized on the outside of the protein, in an area in contact with other monomers and thus crucial for protein function. Another interesting example is the case of mutation E174K, one of the most frequent TNSALP gene mutations in Caucasian populations which is always associated with moderate forms of hypophosphatasia (9, 14, 16) . With 88% of wild-type activity, this mutation could result in very moderately lowered ALP production which would be enough to induce the disease. However, it may also result in a problem that does not affect ALP activity, defective intracellular transport, for instance. It is also possible that the in vivo residual activity of E174K would be less than its in vitro activity. The fact that the residue belongs to a surface domain that could interact with the C-terminal end involved in GPI attachment or with another dimer to form a tetramer may explain its pathogenic effect. The fact that the E174 residue was found completely on the molecule's surface may explain why this effect was moderate. Indeed, such an outlying position in the molecule is probably only sensitive to polarity changes, and the substitution Glu→Lys maintains the polarity properties of the residue. Among the mechanisms by which mutations disrupt TNS-ALP function are defective protein production, processing, interactions between subunits of the homotetramer and GPI attachment. These mutations result in a great variety of hypophosphatasia phenotypes ranging from neonatal to late onset forms. ALP measurements of transfected cells allowed us to determine whether the TNSALP product is functional or not, and to estimate its proportion when compared with the wildtype product. The results provide strong evidence that phenotypic heterogeneity was due mostly to allelic heterogeneity and that transient expression of mutagenized cDNAs is a useful tool for genotype-phenotype correlation, even if individual variation either in levels of synthesis of mutant enzymes or in catabolic activities may also play a role in the expression of the phenotype, as shown by patients exhibiting the same genotype but distinct phenotypes. Although it is not always possible to extrapolate in vitro results to in vivo features, the good correlation observed between clinical data and transfection studies suggests that this methodology may be used reliably for most missense mutations of the TNSALP gene. However, the limits of our study are such that there may be mutations exhibiting residual in vitro activity but for which the protein may be incompletely processed or incorrectly addressed to the cell membrane. Such severe alleles could be classified as moderate alleles if the mutant protein is not degraded rapidly and completely. Immunoprecipitation studies and phosphatidylinositol-specific phospholipase C (PI-PLC) treatment of mutagenized cells may show whether the mutant TNSALP has been converted to the mature form by terminal glycosylation and transported to the cell surface (17) . However, such studies are time-consuming and costly and could be envisaged only for particular mutations, for instance when the residual activity of the mutant does not match clinical data or three-dimensional modelling. In the light of our work, some particular regions of the protein appear as good candidates for further studies of GPI attachment and homodimer interactions. Analysis of novel mutations found in patients with hypophosphatasia, as well as site-directed mutagenesis of residues from these regions and three-dimensional modelling, may help to understand particular cases of hypophosphatasia such as late onset forms exhibiting dominant transmission.
In conclusion, the good correlation of clinical data and sitedirected mutagenesis results allowed us to distinguish severe and moderate alleles in certain patients affected by non-lethal hypophosphatasia. A three-dimensional model based on the E.coli ALP crystal structure allowed us to specify the peptide domains of these amino acid changes, to attempt to understand the mutation effects and to provide a basic model for further studies of mutations responsible for hypophosphatasia.
MATERIALS AND METHODS
Site-directed mutagenesis
Thirteen mutations, mostly missense mutations found in patients with non-lethal forms of hypophosphatasia, were studied: S-1F, A23V, M45L, G58S, R119H, H154Y, G145V, E174K, W253X, E274K, S428P, R433C and R374C. In addition, the Y246H polymorphism was studied.
A full-length wild-type cDNA of the TNSALP gene was obtained from amniotic cells of a normal fetus by RT-PCR using the Pyrococcus furiosis (Pfu) DNA polymerase (Stratagene, La Jolla, CA) and standard molecular biology methods. The primers used were GGGGTGCACCATGATTT-CACC (forward) and AAGGGGGGGCTGCCGTGTGGGAA (reverse). The PCR product was cloned into the TOPO2 vector (Invitrogen, Carlsbad, CA) and completely sequenced to make sure that the sequence was normal. The mutations were introduced into the normal cDNA by PCR using oligonucleotides containing the desired change (23) . The sequences of the mutated primers are shown in Table 4 . DNA from plasmid TOPO2 was amplified with Pfu DNA polymerase in two overlapping segments, each using one oligonucleotide corresponding to either the 5' or 3' end of the TNSALP-coding sequence. The 5' and 3' amplified segments were then gel purified, combined in a single reaction mixture, denatured, annealed and extended to produce a full-length molecule containing the mutant sequence, which was then amplified by using the primers from the 5' and 3' ends of the coding sequence. The complete sequence of each construct was checked to ensure that no unwanted mutations had been introduced by the PCR. The inserts were next subcloned into the expression vector pcDNA3.1 His B (Invitrogen) for expression studies.
Alternatively, mutated cDNAs were obtained directly from the normal cDNA cloned into pCDNA3.1 His B by using the Quikchange Site-Directed Mutagenesis kit (Stratagene). Briefly, oligonucleotides containing the desired change were annealed to the vector (~50 ng) containing the wild-type cDNA and extended during temperature cycling by means of PfuTurbo DNA polymerase (Statagene), generating a mutated plasmid containing staggered nicks. The PCR product was treated with 10 U of DpnI restriction enzyme to hydrolyse methylated or hemimethylated parental DNA, and transformed into E.coli (Epicurian Coli XL1-blue supercompetent cells; Stratagene). The presence of the desired mutation was checked by sequencing. 
ALP assays
The medium was removed, and cells were washed with cold phosphate-buffered saline (PBS) and lysed in 0.5 ml of lysis buffer (1% Triton X-100, 0.5% sodium deoxycholate, 0.05% SDS) in PBS as described previously (24) . A protease inhibitor mix (antipain, aprotinin, chymostatin, elastatinal, leupeptin and pepstatin A; 10 µg/ml of each) was added to cell lysates and media. The cell lysates were incubated for 20 min at 37°C to extract TNSALP according to a previously described methodology (25) . The lysates and media were centrifuged at 15 000 g for 10 min to remove insoluble material. ALP activities were determined using a VP Abbott bichromatic autoanalyser with commercially available kits. Total activity was measured by incubating 25 µl of tissue extract with 250 µl of A-Gent phosphatase alkaline Abbott reagent (18 mmol/l p-nitrophenyl-1,3-propanediol) for 12 min at 37°C and by monitoring the absorbance at 415-450 nm. The results were expressed as a percentage of wild-type cDNA activity (%WT) taken as reference, and a cDNA containing the mutation W253X was used as negative control in the experiments. Each ALP assay was repeated at least twice in independent experiments. β-Galactosidase activity was measured in duplicate as described previously (26) .
Computer-assisted modelling
A three-dimensional model of human TNSALP was built using alignment to the known three-dimensional structure of E.coli ALP (PDB code 1ALK) as a template (20) . Because the quality of the model obtained by homology modelling is critically dependent on the accuracy of the initial sequence alignment, this alignment was carried out with a program that only permits insertions and deletions in regions corresponding to loops in the structure of E.coli ALP (J.-F. Gibrat, unpublished data). The consistency of the final alignment was then checked with a multiple sequence alignment of 21 various ALPs with <90% homology between themselves and >30% homology with the E.coli sequence, making sure that highly conserved residues in the multiple alignment were also aligned in the pair alignment. On the basis of this pair alignment, 10 models were generated with the program Modeller 4 (27) , and the model with the lowest energy was selected. This model was then analysed with the molecular visualization program RasMol v2.5 (R. Sayle, Glaxo Research and Development, Greenford, Middlesex, UK). For each residue affected by a missense mutation, the location of the residue in the three-dimensional structure and the changes caused by the mutation that may disrupt protein function (hydrogen bond pattern, bulkiness, hydrophobicity, etc.) were noted.
